Ulta Beauty (ULTA) is an Illinois-based cosmetics and beauty product retailer. The company has more than 1,200 operations across the U.S.
And ULTA recently posted blowout second-quarter financials…
The company’s earnings per share were $4.45 versus the expected $2.57. ULTA’s revenue was $1.97 billion, topping the $1.77 billion estimate. The cosmetic retailer’s comparable-store sales surged by 56.3%, beating the anticipated 46.9%.
This pushed ULTA to provide strong guidance as well. For fiscal year 2022, ULTA said EPS could come in at around $14.50 to $14.70. The company previously projected EPS of $11.50 to $11.95.
Meanwhile, ULTA highlighted that revenue could be $8.1 billion to $8.3 billion, greater than its previous guidance of $7.7 billion to $7.8 billion. The company projects comparable-store sales will rise by another 30% to 32% as well.
These solid results left a positive impression on analysts. And investment advisory Oppenheimer maintained its “outperform” rating for ULTA shares as a result.
Oppenheimer also increased its price target range from $385 to $415, signaling the company could see major share growth in the months ahead as cosmetics demand continues to remain elevated.
The Alzheimer's Association estimates that, “caring for individuals with Alzheimer's will cost American society $20 trillion.”
Jim Cramer says a drug that could treat the disease “would be the biggest drug ever.”
The Wall Street Journal says the “financial benefits would be massive.”
One small biotech holds the key to a revolution in treating this dreaded disease.
Jeff Bezos, Goldman Sachs & a Big Pharma giant have invested billions into this unknown biotech.
And our research shows that anyone who gets in today could turn every $1,000 into $1.1 million.